Several novel immunotherapies, including autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy, anti‐CD20 × anti‐CD3 bispecific antibody, and CD79b‐targeted antibody‐drug conjugate, have been studied for the treatment of rel/ref B‐cell lymphoma.22, 23, 24, 25. The gene discussed is CD79B; the disease is B-cell non-Hodgkin lymphoma.